Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes
Status:
Not yet recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
A 2-arm randomized Phase II Open Label Study to evaluate the safety and feasibility of
intralymphatic administration of Diamyd® (Diamyd) in individuals at risk of Type 1 diabetes
carrying the HLA DR3-DQ2 haplotype.